Search research articles
Contact Us
Filters
Showing results (31-40 of 105) with videos related to
Page
of 11
Sort By:
Haematologica
|
August 12, 2017
CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib
Josephine M Vos, Nickolas Tsakmaklis, Christopher J Patterson, et al.
Leukemia & Lymphoma
|
June 11, 2011
Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells
Jenny Y Sun, Hsiuyi Tseng, Lian Xu, et al.
Blood Advances
|
August 22, 2020
Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up
Jorge J Castillo, Kirsten Meid, Catherine A Flynn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 10, 2008
Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs
Xavier Leleu, Jacob Soumerai, Aldo Roccaro, et al.
Blood
|
November 19, 2008
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia
Steven P Treon, Andrew R Branagan, Leukothea Ioakimidis, et al.
Oncotarget
|
April 21, 2017
The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions
Antonio Sacco, Adriano Fenotti, Loredana Affò, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 13, 2016
Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214)
Steven P Treon, Kirsten Meid, Christina Tripsas, et al.
Clinical Lymphoma & Myeloma
|
February 28, 2007
Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy
Evdoxia Hatjiharissi, Mark Hansen, Daniel Ditzel Santos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 15, 2020
Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia
Steven P Treon, Kirsten Meid, Joshua Gustine, et al.
Seminars in Hematology
|
May 25, 2025
Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom's Macroglobulinemia
Shayna Sarosiek, Anne-Marie L Becking, Andrew Branagan, et al.
Page
of 11
Search research articles
Search
Showing results (31-40 of 105) with videos related to
Sort By:
Page
of 11
Haematologica
|
August 12, 2017
CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib
Josephine M Vos, Nickolas Tsakmaklis, Christopher J Patterson, et al.
Leukemia & Lymphoma
|
June 11, 2011
Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells
Jenny Y Sun, Hsiuyi Tseng, Lian Xu, et al.
Blood Advances
|
August 22, 2020
Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up
Jorge J Castillo, Kirsten Meid, Catherine A Flynn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 10, 2008
Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs
Xavier Leleu, Jacob Soumerai, Aldo Roccaro, et al.
Blood
|
November 19, 2008
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia
Steven P Treon, Andrew R Branagan, Leukothea Ioakimidis, et al.
Oncotarget
|
April 21, 2017
The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions
Antonio Sacco, Adriano Fenotti, Loredana Affò, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 13, 2016
Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214)
Steven P Treon, Kirsten Meid, Christina Tripsas, et al.
Clinical Lymphoma & Myeloma
|
February 28, 2007
Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy
Evdoxia Hatjiharissi, Mark Hansen, Daniel Ditzel Santos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 15, 2020
Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia
Steven P Treon, Kirsten Meid, Joshua Gustine, et al.
Seminars in Hematology
|
May 25, 2025
Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom's Macroglobulinemia
Shayna Sarosiek, Anne-Marie L Becking, Andrew Branagan, et al.
Page
of 11